LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
Qiagen's "Day-One" lab readiness program is designed to expedite patient access to its CDx tests following regulatory approval of the tests and associated drugs.
A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.
At the Personalized Medicine Conference this week, stakeholders historically at odds over lab test regulation said it is up to Congress to resolve the issue.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.
